In conclusion, our results systematically demonstrated the expression, potential function, and prognostic value of the m6A RNA methylation regulator FTO in STAD, contributing to tumor gene-targeting therapy and clinical prognosis study. This evidence concerns the gene METTL3 and neoplasm.